Objective To research the efficacy and security of two different budesonide formulations (effervescent tablet for orodispersible use (Wager) and viscous suspension system (BVS)) with different daily dosages for short-term treatment of eosinophilic oesophagitis (EoE). of budesonide (Wager1, Wager2, BVS, respectively) and in 0% of placebo recipients (p 0.0001). The improvement altogether endoscopic intensity rating was… Continue reading Objective To research the efficacy and security of two different budesonide